Momenta Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Momenta Pharmaceuticals's estimated annual revenue is currently $75M per year.(i)
  • Momenta Pharmaceuticals's estimated revenue per employee is $842,697
  • Momenta Pharmaceuticals's total funding is $39.5M.

Employee Data

  • Momenta Pharmaceuticals has 89 Employees.(i)
  • Momenta Pharmaceuticals grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars (polysaccharides) for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. We are also utilizing our ability to sequence, or analyze the molecular structure of, sugars to create technology-enabled generic versions of complex sugar-based products. Our most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox®, a widely prescribed low molecular weight heparin, or LMWH. Our novel product candidates include M118, a LMWH for the treatment of acute coronary syndromes that has been designed to possess specific biological attributes as well as a technology that has been designed to use specific sugar sequences to improve the non-invasive delivery of drugs such as therapeutic proteins.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Momenta Pharmaceuticals News

2022-04-17 - Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Size ...

... GlaxoSmithKline plc, HanAllBiopharma, Janssen Global Services, LLC, Leo Pharma, LG Chem, AstraZeneca, Momenta Pharmaceuticals,...

2022-04-06 - Innovation leader | UDaily

Korley has firsthand experience in entrepreneurship. Immediately prior to graduate school, he worked at Momenta Pharmaceuticals (MNTA) when it...

2022-03-22 - Stock Watch: The Meaning Of Biosimilar Success

... acquires a failed drug from big pharma and plans to repeat the ... new biosimilar biotech companies like Momenta Pharmaceuticals,...

2017-02-21 - Bad news for Momenta and Pfizer is a much-needed blessing for Teva

File this under “reversal of fortunes.” Late last Friday, Momenta Pharmaceuticals disclosed that a Pfizer plant contracted to make a generic version of a best-selling multiple sclerosis medicine was slapped with a warning letter by the US Food and Drug Administration. This means Momenta will su ...

2009-08-13 - Turmoil at the FDA? — MedCity Morning Read, Aug. 13, 2009

Momenta says the co-authored paper represents a conflict of interest and asked that Woodcock excuse herself from the blood thinner approval process. The FDA says it’s aware of the complaint, but Woodcock had not removed herself from the process, the Journal said. On Tuesday, the FDA’s top med ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding